Briefly, the clinical model was improved for various CV outcomes as follows: troponin and BNP for CV death alone and combined CV death, MI, or stroke; troponin, BNP, and trail receptor 2 (TRAILR2) for all-cause mortality and combined CV death or HF hospitalization; BNP and galectin 9 (Gal-9) for HF hospitalization; troponin, FGF23, and alpha-1-microglobulin/bikunin precursor (AMBP) for MI; and troponin alone for stroke. The gene discussed is TNFRSF10B; the disease is stroke disorder.